Literature DB >> 17710228

Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.

Liping Song1, Tasnim Ara, Hong-Wei Wu, Chan-Wook Woo, C Patrick Reynolds, Robert C Seeger, Yves A DeClerck, Carol J Thiele, Richard Sposto, Leonid S Metelitsa.   

Abstract

Valpha24-invariant natural killer T (NKT) cells are potentially important for antitumor immunity. We and others have previously demonstrated positive associations between NKT cell presence in primary tumors and long-term survival in distinct human cancers. However, the mechanism by which aggressive tumors avoid infiltration with NKT and other T cells remains poorly understood. Here, we report that the v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (MYCN), the hallmark of aggressive neuroblastoma, repressed expression of monocyte chemoattractant protein-1/CC chemokine ligand 2 (MCP-1/CCL2), a chemokine required for NKT cell chemoattraction. MYCN knockdown in MYCN-amplified neuroblastoma cell lines restored CCL2 production and NKT cell chemoattraction. Unlike other oncogenes, MYCN repressed chemokine expression in a STAT3-independent manner, requiring an E-box element in the CCL2 promoter to mediate transcriptional repression. MYCN overexpression in neuroblastoma xenografts in NOD/SCID mice severely inhibited their ability to attract human NKT cells, T cells, and monocytes. Patients with MYCN-amplified neuroblastoma metastatic to bone marrow had 4-fold fewer NKT cells in their bone marrow than did their nonamplified counterparts, indicating that the MYCN-mediated immune escape mechanism, which we believe to be novel, is operative in metastatic cancer and should be considered in tumor immunobiology and for the development of new therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17710228      PMCID: PMC1940236          DOI: 10.1172/JCI30751

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  69 in total

Review 1.  Transcriptional repression by Myc.

Authors:  Michael Wanzel; Steffi Herold; Martin Eilers
Journal:  Trends Cell Biol       Date:  2003-03       Impact factor: 20.808

Review 2.  Progressive differentiation and selection of the fittest in the immune response.

Authors:  Antonio Lanzavecchia; Federica Sallusto
Journal:  Nat Rev Immunol       Date:  2002-12       Impact factor: 53.106

3.  Repression of the TMEFF2 promoter by c-Myc.

Authors:  Sigal Gery; H Phillip Koeffler
Journal:  J Mol Biol       Date:  2003-05-16       Impact factor: 5.469

4.  A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.

Authors:  Giuseppe Giaccone; Cornelis J A Punt; Yoshitaka Ando; Rita Ruijter; Nobusuke Nishi; Marlies Peters; B Mary E von Blomberg; Rik J Scheper; Hans J J van der Vliet; Alfons J M van den Eertwegh; Marja Roelvink; Jos Beijnen; Heinz Zwierzina; Herbert M Pinedo
Journal:  Clin Cancer Res       Date:  2002-12       Impact factor: 12.531

5.  Biological classification of cell lines derived from human extra-cranial neural tumors.

Authors:  C P Reynolds; M M Tomayko; L Donner; L Helson; R C Seeger; T J Triche; G M Brodeur
Journal:  Prog Clin Biol Res       Date:  1988

6.  Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc.

Authors:  E M Blackwood; R N Eisenman
Journal:  Science       Date:  1991-03-08       Impact factor: 47.728

7.  Analysis of avian leukosis virus DNA and RNA in bursal tumours: viral gene expression is not required for maintenance of the tumor state.

Authors:  G S Payne; S A Courtneidge; L B Crittenden; A M Fadly; J M Bishop; H E Varmus
Journal:  Cell       Date:  1981-02       Impact factor: 41.582

Review 8.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

9.  The MYC protein activates transcription of the alpha-prothymosin gene.

Authors:  M Eilers; S Schirm; J M Bishop
Journal:  EMBO J       Date:  1991-01       Impact factor: 11.598

10.  Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line.

Authors:  K Matsushima; C G Larsen; G C DuBois; J J Oppenheim
Journal:  J Exp Med       Date:  1989-04-01       Impact factor: 14.307

View more
  50 in total

1.  CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells.

Authors:  Akihiro Tsuyada; Amy Chow; Jun Wu; George Somlo; Peiguo Chu; Sofia Loera; Thehang Luu; Arthur Xuejun Li; Xiwei Wu; Wei Ye; Shiuan Chen; Weiying Zhou; Yang Yu; Yuan-Zhong Wang; Xiubao Ren; Hui Li; Peggy Scherle; Yukio Kuroki; Shizhen Emily Wang
Journal:  Cancer Res       Date:  2012-04-03       Impact factor: 12.701

Review 2.  Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans.

Authors:  Leonid S Metelitsa
Journal:  Clin Immunol       Date:  2010-11-20       Impact factor: 3.969

3.  Macrophage p38 mitogen-activated protein kinase activity regulates invariant natural killer T-cell responses during Borrelia burgdorferi infection.

Authors:  Kelly Hawley; Nicolás Navasa; Chris M Olson; Tonya C Bates; Renu Garg; Michael N Hedrick; Dietrich Conze; Mercedes Rincón; Juan Anguita
Journal:  J Infect Dis       Date:  2012-05-02       Impact factor: 5.226

4.  Interleukin-23 engineering improves CAR T cell function in solid tumors.

Authors:  Xingcong Ma; Yang Xu; Peishun Shou; Christof Smith; Yuhui Chen; Hongwei Du; Chuang Sun; Nancy Porterfield Kren; Daniel Michaud; Sarah Ahn; Benjamin Vincent; Barbara Savoldo; Yuliya Pylayeva-Gupta; Shuqun Zhang; Gianpietro Dotti
Journal:  Nat Biotechnol       Date:  2020-02-03       Impact factor: 54.908

5.  Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma.

Authors:  Presha Rajbhandari; Gonzalo Lopez; Claudia Capdevila; Beatrice Salvatori; Jiyang Yu; Ruth Rodriguez-Barrueco; Daniel Martinez; Mark Yarmarkovich; Nina Weichert-Leahey; Brian J Abraham; Mariano J Alvarez; Archana Iyer; Jo Lynne Harenza; Derek Oldridge; Katleen De Preter; Jan Koster; Shahab Asgharzadeh; Robert C Seeger; Jun S Wei; Javed Khan; Jo Vandesompele; Pieter Mestdagh; Rogier Versteeg; A Thomas Look; Richard A Young; Antonio Iavarone; Anna Lasorella; Jose M Silva; John M Maris; Andrea Califano
Journal:  Cancer Discov       Date:  2018-03-06       Impact factor: 39.397

6.  Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition.

Authors:  Serena K Perna; Daria Pagliara; Aruna Mahendravada; Hao Liu; Malcolm K Brenner; Barbara Savoldo; Gianpietro Dotti
Journal:  Clin Cancer Res       Date:  2013-10-04       Impact factor: 12.531

7.  Mitochondrial DNA Haplogroups and Susceptibility to Neuroblastoma.

Authors:  Xiao Chang; Marina Bakay; Yichuan Liu; Joseph Glessner; Komal S Rathi; Cuiping Hou; Huiqi Qu; Zalman Vaksman; Kenny Nguyen; Patrick M A Sleiman; Sharon J Diskin; John M Maris; Hakon Hakonarson
Journal:  J Natl Cancer Inst       Date:  2020-12-14       Impact factor: 13.506

8.  Induction of chemokine (C-C motif) ligand 2 by sphingosine-1-phosphate signaling in neuroblastoma.

Authors:  Mei-Hong Li; Miriam Harel; Timothy Hla; Fernando Ferrer
Journal:  J Pediatr Surg       Date:  2014-05-16       Impact factor: 2.545

Review 9.  More than the genes, the tumor microenvironment in neuroblastoma.

Authors:  Lucia Borriello; Robert C Seeger; Shahab Asgharzadeh; Yves A DeClerck
Journal:  Cancer Lett       Date:  2015-11-17       Impact factor: 8.679

10.  MYCN-targeting vaccines and immunotherapeutics.

Authors:  Alexander Schramm; Holger Lode
Journal:  Hum Vaccin Immunother       Date:  2016-04-20       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.